A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Astrazeneca's EVP – International shares how the company is working to deliver healthcare that is inclusive, impactful and ...

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

AstraZeneca, a globally leading biopharmaceutical company, kicked off construction on a new small molecule drug manufacturing ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...